title: Lactobacillus casei reduces the inflammatory joint damage associated with collagen-induced arthritis (CIA) by reducing the pro-inflammatory cytokines: Lactobacillus casei: COX-2 inhibitor.
abstract: This study evaluated the therapeutic efficacy of Lactobacillus casei in treating rheumatoid arthritis using collagen-induced arthritis (CIA) animal model. Healthy female Wistar rats (weight-180-200 g) were included in this study. Oral administration of L. casei was started on the same day. Indomethacin was used as standard reference drug. Serum level of IL-6, α-TNF, and IL-10 were observed. Four-point arthritis indexes were also assessed at the end of week for 28th day. L. casei-treated rats had shown normal histopathology without any synovial infiltration, pannus formation, cartilage, and bone destruction. Arthritis score was also lower for the group treated with L. casei. Oral administration of L. casei significantly decreased the pro-inflammatory cytokines. Present study suggests that L. casei has potent antiarthritic effect in CIA model. Inhibition of COX-2 via inhibiting the pro-inflammatory cytokines is an understanding of the complex interactions involved in these pathways.
authors.affiliation: Department of Microbiology, Barkatullah University, Hoshangabad Road, Bhopal, 462026 Madhya Pradesh, India. ananyasarika@gmail.com
authors.forename: Sarika
authors.initials: S
authors.lastname: Amdekar
authors.forename: Vinod
authors.initials: V
authors.lastname: Singh
authors.forename: Rambir
authors.initials: R
authors.lastname: Singh
authors.forename: Poonam
authors.initials: P
authors.lastname: Sharma
authors.forename: Poonam
authors.initials: P
authors.lastname: Keshav
authors.forename: Avnish
authors.initials: A
authors.lastname: Kumar
mesh_terms: D000284:Administration, Oral; D000818:Animals; D001169:Arthritis, Experimental / Q000276:immunology / Q000473:pathology / Q000628:therapy; D052246:Cyclooxygenase 2 Inhibitors / Q000627:therapeutic use*; D016207:Cytokines / Q000097:blood* / Q000276:immunology; D004195:Disease Models, Animal; D005260:Female; D005786:Gene Expression Regulation / Q000187:drug effects; D007167:Immunotherapy; D007213:Indomethacin / Q000494:pharmacology / Q000627:therapeutic use; D007596:Joints / Q000187:drug effects / Q000276:immunology / Q000473:pathology*; D007780:Lacticaseibacillus casei / Q000276:immunology*; D008954:Models, Biological; D019936:Probiotics; D011897:Random Allocation; D051381:Rats; D017208:Rats, Wistar; D012720:Severity of Illness Index
chemical_list: D052246:Cyclooxygenase 2 Inhibitors; D016207:Cytokines; D007213:Indomethacin